Adalvo is pleased to announce that it has entered into a partnership with Juno Pharmaceuticals Canada, to commercialize a number of respiratory and dermatology dossiers. This licensing and supply agreement includes a basket of three products covering several indications, including Allergic Rhinitis, Rosacea, and Atopic Dermatitis.
Anil Okay, CEO at Adalvo comments: “We are thrilled to be collaborating with Juno Canada. Working together enables Adalvo to further strengthen our offering of respiratory and dermatology products, emphasizing our dedication to patient care and extending our global reach”
Mark Mantel, CEO at Juno Canada comments: “Collaborating with Adalvo aligns perfectly with our mission to provide groundbreaking healthcare solutions. Together, we look forward to introducing a range of innovative products that make a meaningful impact on the lives of patients.”
Interested in finding out more about Adalvo's respiratory and dermatology products? Get in touch today.
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 100 countries and for over 110 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners.
With headquarters in Malta, the company has additional offices in more than 16 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customized to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals.
We take pride in our ability to help partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities.
The company’s purpose driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
About Juno Canada
Juno Pharmaceuticals Canada specializes in manufacturing, developing, and delivering high-quality, cost-effective, complex,and high value generic, branded and biosimilar products. With operations in Toronto and Montreal, Juno is one of the largest generic injectable businesses in Canada with domestic manufacturing capabilities and a robust distribution pipeline throughout 22 international markets. An early member of the global Juno Pharmaceuticals group, Juno’s global operations span four continents and consist of over 14 diverse pharmaceutical and medical device businesses spread across Canada, the United Kingdom, the European Union, Australia, and South Africa.